| Literature DB >> 27025637 |
Nguyen T Nhung1, Cao T Thuy2, Nguyen V Trung3,4, James Campbell5,6, Stephen Baker7,8, Guy Thwaites9,10, Ngo T Hoa11,12, Juan Carrique-Mas5,6.
Abstract
In Vietnam, commercial disinfectants containing quaternary ammonium compounds (QACs) are commonly used in pig and poultry farms to maintain hygiene during production. We hypothesized that sustained exposure to sub-bactericidal concentrations of QAC-based disinfectants may result in increased levels of antimicrobial resistance (AMR) among Enterobacteriacea due to the increase of efflux pump expression. To test this hypothesis we exposed six antimicrobial-susceptible Escherichia coli (E. coli) and six antimicrobial-susceptible non-typhoidal Salmonella (NTS) isolates to increasing concentrations of a commonly used commercial disinfectant containing a mix of benzalkonium chloride and glutaraldehyde. Over the 12-day experiment, strains exhibited a significant change in their minimum inhibitory concentration (MIC) of the disinfectant product (mean increase of 31% (SD ± 40)) (p = 0.02, paired Wilcoxon test). Increases in MIC for the disinfectant product were strongly correlated with increases in MIC (or decreases in inhibition zone) for all antimicrobials (Pearson's correlation coefficient 0.71-0.83, all p < 0.01). The greatest increases in MIC (or decreases in inhibition zone) were observed for ampicillin, tetracycline, ciprofloxacin, and chloramphenicol, and the smallest for gentamicin, trimethoprim/sulphamethoxazole. The treatment of 155 representative E. coli isolates from farmed and wild animals in the Mekong Delta (Vietnam) with phenyl-arginine beta-naphthylamide (PAβN), a generic efflux pump inhibitor, resulted in reductions in the prevalence of AMR ranging from 0.7% to 3.3% in these organisms, indicating a small contribution of efflux pumps on the observed prevalence of AMR on farms. These results suggest that the mass usage of commercial disinfectants, many of which contain QACs, is potentially a contributing factor on the generation and maintenance of AMR in animal production in Vietnam.Entities:
Keywords: adaptation; antimicrobials; disinfectant; efflux pumps
Year: 2015 PMID: 27025637 PMCID: PMC4790309 DOI: 10.3390/antibiotics4040480
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Minimum inhibitory concentrations (MIC) against studied strains for Product A. Columns 3, 4, and 6 show MICs (μg/mL) pre-exposure, post-exposure, and after treatment with efflux pump inhibitor (PAβN). Column 5 shows changed MIC levels (%) after exposure to Product A compared with pre-exposure levels. Column 7 shows the average decreased MIC (%) after treatment with efflux pump inhibitor compared with post-exposure levels.
| Strain ID | Species | Average MIC (µg/mL) | Average Change in MIC after Exposure | Average MIC (µg/mL) | Average Change in MIC after Treatment with PAβN | |
|---|---|---|---|---|---|---|
| Pre-exposure | Post-exposure | after Treatment with PAβN | ||||
| S01 | 21 | 21 | 0% | 15 | −29% | |
| S02 | 24 | 33 | +38% | 24 | −27% | |
| S03 | 24 | 33 | +38% | 27 | −18% | |
| S04 | 30 | 60 | +100% | 36 | −40% | |
| S05 | 24 | 36 | +50% | 30 | −17% | |
| SC | 24 | 24 | 0% | 24 | 0% | |
| E01 | 15 | 15 | 0% | 15 | 0% | |
| E02 | 27 | 24 | −11% | 15 | −38% | |
| E03 | 12 | 12 | 0% | 12 | 0% | |
| E04 | 12 | 24 | +100% | 18 | −25% | |
| E05 | 27 | 42 | +56% | 33 | −21% | |
| EC | 12 | 12 | 0% | 12 | 0% | |
| All isolates (mean ± SD) | 21 (SD ± 6) | 27 (SD ± 12) | +31% (SD ± 40%) | 21 (SD ± 9) | −18% (SD ± 15%) | |
SD: Standard deviation; * Laboratory reference strains.
Figure 1Correlation between changes in MIC for Product A and changes in MIC for gentamicin, chloramphenicol, ciprofloxacin, trimethoprim/sulphamethoxazole, and tetracycline. The size of each dot is proportional to the number of strains.
MIC against studied strains for gentamicin, chloramphenicol, ciprofloxacin, trimethoprim/sulphamethoxazole, and tetracycline; zone inhibition diameter for ampicillin before exposure to Product A, after exposure to Product A, and after treatment with efflux pump inhibitor (PAβN). The p-values were obtained using paired Wilcoxon tests for the comparisons: † before and after exposure to Product A; § after exposure to Product A and after treatment with efflux pump inhibitor.
| Antimicrobial | Mean (±SD) (µg/mL) | Mean Change (%) (±SD) | Mean (±SD) (µg/mL) | Mean Change (%) (±SD) | |||
|---|---|---|---|---|---|---|---|
| Pre-exposure | Post-exposure | After Treatment with PAβN | |||||
| Gentamicin * | 1.12 (±0.29) | 1.29 (±0.26) | +18 (±23) | 0.053 | 1.21 (±0.26) | −6 (±13) | 0.346 |
| Chloramphenicol * | 6.50 (±1.51) | 13.67 (±9.22) | +106 (±135) | 0.035 | 7.83 (±3.35) | −24 (±32) | 0.059 |
| Ciprofloxacin * | 0.03 (±0.01) | 0.11 (±0.09) | +316 (±363) | 0.034 | 0.12 (±0.10) | −1 (±20) | 1.0 |
| Trimethoprim/sulphamethoxazole * | 0.09 (±0.02) | 0.14 (±0.06) | +58 (±55) | 0.014 | 0.12 (±0.05) | −7 (±17) | 0.371 |
| Tetracycline * | 2.42 (±0.90) | 23.29 (±25.98) | +776 (±1027) | 0.001 | 21.92 (±25.02) | −1 (±22) | 0.423 |
| Ampicillin ** | 18.6 (±1.5) | 12.0 (±6.4) | +35 (±35) | 0.014 | 11.8 (±6.2) | −1 (±3) | 1.0 |
*MIC (µg/mL); **Diameter of zone inhibition (mm); SD: Standard Deviation.
Figure 2MIC (µg/mL) for antimicrobials of 12 strains before (○) and after (●) exposure experiment; controls of adaptation experiment (∇) and after treatment with efflux pump inhibitor PAβN (x). Vertical black lines: breakpoints for susceptible (on the left), intermediate (between two lines), and resistant (on the right) classes based on Clinical and Laboratory Standard Institute (CLSI) guidelines. For ampicillin, changes in inhibition zone diameter (mm) shown, with full resistance on the left and susceptibility on the right. Breakpoints for gentamicin (≤4 µg/mL, sensitive), ciprofloxacin (≤1 µg/mL, sensitive), and trimethoprim/sulphamethoxazole (≤2 µg/mL, sensitive) not shown since outside the range. * Strains did not increase MIC for Product A.
Prevalence (%) of antimicrobial resistance among 155 representative E. coli isolates from animals before and after treatment with efflux pump inhibitor (PAβN).
| Antimicrobial | Before Treatment with PAβN | After Treatment with PAβN | Relative Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | R | I+R | S | I | R | I+R | ||
| Gentamicin | 80.0 | 5.2 | 14.8 | 20.0 | 80.7 | 4.5 | 14.8 | 19.3 | −0.7 |
| Chloramphenicol | 43.8 | 5.2 | 51.0 | 56.2 | 47.1 | 1.9 | 51.0 | 52.9 | −3.3 |
| Ciprofloxacin | 70.3 | 12.9 | 16.8 | 29.7 | 72.9 | 10.3 | 16.8 | 27.1 | −2.6 |
| Trimethoprim/sulphamethoxazole | 40.0 | 1.3 | 58.7 | 60.0 | 40.0 | 1.3 | 58.7 | 60.0 | 0 |
| Tetracycline | 23.9 | 0.1 | 76.0 | 76.1 | 23.9 | 0.1 | 76.0 | 76.1 | 0 |
| Ampicillin | 12.9 | 16.1 | 71.0 | 87.1 | 15.5 | 21.3 | 63.2 | 84.5 | −2.6 |
S: Fully sensitive; I: Intermediate resistant; R: Fully resistant.